Skip to main content
OpenTrials
Completed

NCT Number: NCT04068285

Neuromuscular Adaptations to Exercise In Patients With Type 2 Diabetes Mellitus

The aim of this study is to compare the effects of high intensity interval exercise and moderate intensity continuous exercise on basic gait parameters in patients with type 2 diabetes mellitus.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Volunteers with type 2 diabetes mellitus will be evaluated in terms of any contra-indication that will restrain them from making exercise. 90 male or female volunteers who are suitable in terms of inclusion/exclusion criteria will be invited for the study. Volunteers will be randomly distributed to one of the 3 groups. Each group will contain 30 participants. 1. group will make aerobic exercise which is in the form of high intensity interval exercise 2.group will make aerobic exercise which is in the form of moderate intensity continuous exercise 3. Control group. Exercise groups will be cycling under observation in the hospital setting. Control group will make simple stretching exercises at home. Participants will be requested to complete a 3 months of exercise. They will be evaluated before and at the end of the 3 months of exercise with basic gait parameters such as cadence, gait speed, stride length, percentages of swing phase and stance phase evaluated by a wireless digital miniature gait analysis system.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants must have type 2 Diabetes mellitus less than 10 years and more than 1 year.
  • Participants must have appropriate medical therapy and diet.
  • Participants must not be treated with insulin.
  • Participants must be exercising less than 210 minutes/ week

Exclusion criteria

  • Participants with prominent cardiovascular disease
  • Participants with coronary artery disease
  • Participants with moderate to severe valvular disease
  • Participants with atrial fibrillation
  • Participants with untreated hypertension
  • Participants with congenital heart disease
  • Participants with retinopathy
  • Participants with neuropathy
  • Participants with macro albuminuria
  • Participants with cerebrovascular disease
  • Participants with ejection fraction less than 40
  • Participants with body mass index greater than 35.
  • Participants with prominent ischemic changes in EKG at rest or during exercise.
  • Participants with cigarette or alcohol addiction
  • Participants on drugs that interferes with body fat distribution (such as insulin, thiazolidinediones

Treatment and study plan

Aerobic Exercise

Other

Participants will be making aerobic exercise

Primary outcomes

  1. walking speed

    Time frame: 12 weeks

    change in walking speed in m/s

Sponsors and collaborators

Lead sponsor

Pamukkale University

Other

Registry information

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Aug 28, 2019
Registry last updated
Jun 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.